To the content

Marion Rottenberg is the new International Patient Advocacy Lead at AOP Health

August 29th 2023
The Vienna native has a wealth of experience in pharma and will be building up the European pioneer’s area of Patient Advocacy in the field of rare diseases and intensive care.

Vienna, 29.08.2023. As of June 2023, Marion Rottenberg has taken over the role of International Patient Advocacy Lead at AOP Health. In this position, she is responsible for the strategic expansion of the area and will therefore be working closely with patient organizations. Vienna-born Rottenberg studied Business Management at the Vienna University of Economics and Business. After passing the exam to become a pharma sales representative, she worked in the pharma sector for many years, most recently as a manager in the Marketing & Sales Team of an international pharma company.

Patient concerns as the motivation for change

In her new role, she wants to focus on increasing the visibility of rare diseases and involving patient organizations in the creation of study designs right from the start. The decisive motivator for Rottenberg's switch to AOP Health was the desire to do something for those affected.

Portrait of Marion Rottenberg
Portrait of Marion Rottenberg
Marion Rottenberg

I’m very excited and anticipate a positive effect once patient concerns are brought even more to the forefront – be it in the study design, in the diagnostic phase or in the treatment. Because there’s still a lot to be done in the area of rare diseases.

Petra Lanz, Chief Commercial Officer at AOP Health, is pleased about the new addition to the team.

Portrait of Petra Lanz
Portrait of Petra Lanz
Mag. Petra Lanz

Marion Rottenberg brings an ideal combination of communicative and specialist know-how, making her an ideal choice to firmly establish this new position in the company.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. The claim “Needs. Science. Trust.” sums up the foundation of the Group’s success: establishing trust through a continually high level of investment in research and development and a highly consistent and pragmatic orientation towards the needs of all stakeholders – especially the patients and their families as well as the healthcare professionals treating them.

Press Contact.

Mag. Nina Roth, MAS

Head of Corporate Communications

To the main navigation